Walvax Biotechnology Co., Ltd. (SHE:300142)

Market Cap	18.09B
Revenue (ttm)	2.40B
Net Income (ttm)	49.24M
Shares Out	1.60B
EPS (ttm)	0.03
PE Ratio	367.32
Forward PE	52.00
Dividend	0.03 (0.27%)
Ex-Dividend Date	May 28, 2025

Volume	18,458,170
Average Volume	27,117,936
Open	11.38
Previous Close	11.33
Day's Range	11.27 - 11.39
52-Week Range	9.70 - 14.55
Beta	0.44
RSI	32.78
Earnings Date	Apr 12, 2026

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 2,388
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300142

Financial Performance

In 2024, Walvax Biotechnology's revenue was 2.82 billion, a decrease of -31.41% compared to the previous year's 4.11 billion. Earnings were 142.16 million, a decrease of -66.10%.